申请人:Johns Hopkins University
公开号:EP1825853A2
公开(公告)日:2007-08-29
The present invention includes methods for treatment and prophylaxis of conditions associated with lactosylceramide. The methods generally provide for administration to a mammal, particularly a human, of a therapeutically effective amount of a compound that increases enzymatic activity of UDP Gal:GlcCerβ1→ 4 galactosylceramide (GalT-2). In vitro and in vivo assays for detecting compounds with therapeutic capacity to modulate GaIT-2 are also provided.
本发明包括治疗和预防与乳糖基甘油酰胺有关的疾病的方法。这些方法一般是向哺乳动物,特别是人类施用治疗有效量的化合物,该化合物能提高 UDP Gal:GlcCerβ1→ 4 半乳糖基甘油酰胺(GalT-2)的酶活性。还提供了用于检测具有调节 GaIT-2 治疗能力的化合物的体外和体内试验。